LongBio Pharma(01779.HK): Over-Allotment Option Fully Exercised, Raising Additional Net Proceeds of Approximately HK$194 Million

NewTimeSpace News: On June 30, 2026, LongBio Pharma(01779.HK) issued an announcement stating that the sole sponsor and global coordinator has fully exercised the over-allotment option, covering a total of 2,128,950 H-shares, representing approximately 15% of the total number of shares initially offered for subscription under the global offering.

The over-allotment shares will be allotted and issued at HK$96.06 per share to facilitate the delivery of shares to placees who agreed to deferred settlement of H-shares. The Company will receive additional net proceeds of roughly HK$194 million from the issuance of the over-allotment shares, which will be allocated proportionally for the purposes set out in the prospectus.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.